Guggenheim analyst Seamus Fernandez raised the firm’s price target on Apogee Therapeutics to $44 from $29 and keeps a Buy rating on the shares. The firm is increasing it view on the probability of success and forecast assumptions to reflect increased confidence in APG777 following recent data from YTE-modified antibodies, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APGE:
- Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Apogee Therapeutics initiated with a Buy at BTIG
- Oppenheimer, Wedbush say buy these biotech stocks for 2024
- Apogee Therapeutics expects cash to fund requirements into 4Q26
- Apogee Therapeutics reports Q3 net loss $20.8M vs. $19.7M last year
